DE69232485D1 - VERWENDUNG VON RELAXIN zur Herstellung eines Arzneimittels für die Behandlung KARDIOVASKULÄREN Krankeiten. - Google Patents

VERWENDUNG VON RELAXIN zur Herstellung eines Arzneimittels für die Behandlung KARDIOVASKULÄREN Krankeiten.

Info

Publication number
DE69232485D1
DE69232485D1 DE69232485T DE69232485T DE69232485D1 DE 69232485 D1 DE69232485 D1 DE 69232485D1 DE 69232485 T DE69232485 T DE 69232485T DE 69232485 T DE69232485 T DE 69232485T DE 69232485 D1 DE69232485 D1 DE 69232485D1
Authority
DE
Germany
Prior art keywords
relaxin
treatment
medicament
manufacture
cardiovascular diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232485T
Other languages
English (en)
Other versions
DE69232485T2 (de
Inventor
Michael Cronin
L Osheroff
Roger Thomas
G Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/747,080 external-priority patent/US5166191A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69232485D1 publication Critical patent/DE69232485D1/de
Application granted granted Critical
Publication of DE69232485T2 publication Critical patent/DE69232485T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
DE69232485T 1991-08-19 1992-08-18 VERWENDUNG VON RELAXIN zur Herstellung eines Arzneimittels für die Behandlung KARDIOVASKULÄREN Krankeiten. Expired - Lifetime DE69232485T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/747,080 US5166191A (en) 1991-08-19 1991-08-19 Use of relaxin in cardiovascular therapy
US07/902,637 US5478807A (en) 1991-08-19 1992-06-23 Use of relaxin in the treatment of bradycardia
PCT/US1992/006927 WO1993003755A2 (en) 1991-08-19 1992-08-18 Use of relaxin in cardiovascular therapy and in the treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
DE69232485D1 true DE69232485D1 (de) 2002-04-18
DE69232485T2 DE69232485T2 (de) 2002-11-21

Family

ID=27114692

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232485T Expired - Lifetime DE69232485T2 (de) 1991-08-19 1992-08-18 VERWENDUNG VON RELAXIN zur Herstellung eines Arzneimittels für die Behandlung KARDIOVASKULÄREN Krankeiten.

Country Status (11)

Country Link
US (1) US5478807A (de)
EP (1) EP0600010B1 (de)
JP (1) JP3747058B2 (de)
AT (1) ATE214287T1 (de)
AU (1) AU662923B2 (de)
CA (1) CA2114250C (de)
DE (1) DE69232485T2 (de)
DK (1) DK0600010T3 (de)
ES (1) ES2173868T3 (de)
NZ (1) NZ243970A (de)
WO (1) WO1993003755A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434777T2 (de) * 1993-07-27 2007-06-14 Mario Bigazzi Verwendung von Relaxin zur Herstellung von therapeutischer Mittel
US7069634B1 (en) 1995-04-28 2006-07-04 Medtronic, Inc. Method for manufacturing a catheter
US5811395A (en) * 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
US5911997A (en) * 1995-06-07 1999-06-15 Connetics Corporation Relaxin-like factor and methods and uses thereof
AU6777196A (en) * 1995-08-15 1997-03-12 Connective Therapeutics Inc. Method of promoting angiogenesis
US5612051A (en) * 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
US5846220A (en) * 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease
US7189222B2 (en) 1996-04-30 2007-03-13 Medtronic, Inc. Therapeutic method of treatment of alzheimer's disease
US6627746B1 (en) 1998-04-17 2003-09-30 Exelixis, Inc. Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof
US6251863B1 (en) * 1998-09-08 2001-06-26 Samuel K. Yue Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin
US6266554B1 (en) 1999-02-12 2001-07-24 Cardiac Pacemakers, Inc. System and method for classifying cardiac complexes
US6308095B1 (en) 1999-02-12 2001-10-23 Cardiac Pacemakers, Inc. System and method for arrhythmia discrimination
US6312388B1 (en) 1999-03-12 2001-11-06 Cardiac Pacemakers, Inc. Method and system for verifying the integrity of normal sinus rhythm templates
US6223078B1 (en) 1999-03-12 2001-04-24 Cardiac Pacemakers, Inc. Discrimination of supraventricular tachycardia and ventricular tachycardia events
US6449503B1 (en) 1999-07-14 2002-09-10 Cardiac Pacemakers, Inc. Classification of supraventricular and ventricular cardiac rhythms using cross channel timing algorithm
US6684100B1 (en) 2000-10-31 2004-01-27 Cardiac Pacemakers, Inc. Curvature based method for selecting features from an electrophysiologic signals for purpose of complex identification and classification
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20040006205A1 (en) * 2001-04-03 2004-01-08 Li Li Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6526313B2 (en) 2001-06-05 2003-02-25 Cardiac Pacemakers, Inc. System and method for classifying cardiac depolarization complexes with multi-dimensional correlation
AUPR814401A0 (en) 2001-10-08 2001-11-01 Howard Florey Institute Of Experimental Physiology And Medicine Human 3 relaxin
US6950702B2 (en) 2002-07-15 2005-09-27 Cardiac Pacemakers, Inc. Use of curvature based features for beat detection
US7792571B2 (en) 2003-06-27 2010-09-07 Cardiac Pacemakers, Inc. Tachyarrhythmia detection and discrimination based on curvature parameters
US7878978B2 (en) * 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
CA2559745C (en) * 2004-03-19 2010-11-02 Bas Medical, Inc. Use of relaxin to increase arterial compliance
US7430446B2 (en) 2005-01-20 2008-09-30 Cardiac Pacemakers, Inc. Methods and apparatuses for cardiac arrhythmia classification using morphology stability
JPWO2006118131A1 (ja) * 2005-04-26 2008-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗不安作用を有するペプチドおよびスクリーニング方法
US20060264367A1 (en) * 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
US9314210B2 (en) 2005-06-13 2016-04-19 Cardiac Pacemakers, Inc. Method and apparatus for rate-dependent morphology-based cardiac arrhythmia classification
EP1989144A4 (de) 2006-02-02 2014-01-29 Innovative Bio Therapies Extrakorporale zellbasierte therapeutische vorrichtung und freisetzungssystem
SI2288373T1 (sl) * 2008-05-16 2015-12-31 Corthera, Inc. Relaksin za uporabo pri zdravljenju dispneje, povezane z akutnim srčnim popuščanjem
CN102171332A (zh) 2008-06-18 2011-08-31 创新生物制剂疗法公司 促进肾前体细胞增殖的方法
US9653006B2 (en) 2008-09-17 2017-05-16 Avery Dennison Corporation Activatable adhesive, labels, and related methods
KR101879190B1 (ko) 2009-09-17 2018-07-17 애버리 데니슨 코포레이션 활성화 가능 접착제, 라벨, 및 관련 방법
WO2024047130A1 (en) 2022-08-31 2024-03-07 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Immunosuppressive medicament and method of treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656249A (en) * 1982-06-10 1987-04-07 Howard Florey Institute Of Experimental Physiology And Medicine Peptides with relaxin activity
AU562962B2 (en) * 1982-08-12 1987-06-25 Howard Florey Institute Of Experimental Physiology And Medicine Molecular cloning and characterisation of the gene sequence coding for human relaxin
EP0101309B1 (de) * 1982-08-12 1991-01-16 Howard Florey Institute Of Experimental Physiology And Medicine Molekulare Klonierung und Charakterisierung der das menschliche Relaxin kodierenden Gen-Sequenz
DE3236264A1 (de) * 1982-09-30 1984-04-05 Serono Pharmazeutische Präparate GmbH, 7800 Freiburg Verfahren zur gewinnung von relaxin
DE3236267A1 (de) * 1982-09-30 1984-04-05 Serono Pharmazeutische Präparate GmbH, 7800 Freiburg Verfahren zur herstellung von relaxin und verfahren zur hochreinigung von relaxin
US5023321A (en) * 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
IL70414A (en) * 1982-12-13 1991-06-10 Florey Howard Inst Polypeptide having human h2-relaxin activity,double-stranded dna fragments coding therefor,vectors containing the dna fragments and methods for preparing the polypeptide,dna fragments and vectors
AU562713B2 (en) * 1982-12-13 1987-06-18 Howard Florey Institute Of Experimental Physiology And Medicine Cloning for human relaxin
US4835251A (en) * 1986-06-23 1989-05-30 Genetech, Inc. Method of chain combination
ATE88352T1 (de) * 1988-02-26 1993-05-15 Genentech Inc Humanes relaxinpraeparat.
AU623518B2 (en) * 1989-05-04 1992-05-14 Genentech Inc. Processes and compositions for the isolation of human relaxin
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy

Also Published As

Publication number Publication date
ATE214287T1 (de) 2002-03-15
EP0600010A1 (de) 1994-06-08
AU662923B2 (en) 1995-09-21
JPH06510045A (ja) 1994-11-10
AU2518692A (en) 1993-03-16
NZ243970A (en) 1997-06-24
WO1993003755A2 (en) 1993-03-04
DK0600010T3 (da) 2002-07-01
CA2114250A1 (en) 1993-03-04
WO1993003755A3 (en) 1993-04-01
US5478807A (en) 1995-12-26
JP3747058B2 (ja) 2006-02-22
DE69232485T2 (de) 2002-11-21
ES2173868T3 (es) 2002-11-01
EP0600010B1 (de) 2002-03-13
CA2114250C (en) 2007-10-16

Similar Documents

Publication Publication Date Title
DE69232485T2 (de) VERWENDUNG VON RELAXIN zur Herstellung eines Arzneimittels für die Behandlung KARDIOVASKULÄREN Krankeiten.
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
KR960702318A (ko) 근육 질병 및 장애의 치료방법
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
DE59109222D1 (de) Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen
ATE110958T1 (de) Verwendung von sertralin zur behandlung verfrühter ejakulation.
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
DE69423577D1 (de) Verwendung von Oenothein B zur Herstellung eines Medikaments zur Behandlung der durch Hyperandrogenität bedingte Störungen.
PH23818A (en) Enhancement of activity of alpha-adrenoceptor antagonists
DE69621786T2 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
ATE235237T1 (de) Sertralin zur behandlung von post-myocard-infarkt-patienten
DE69915848D1 (de) Verwendung von neohesperidin dc zur herstellung eines medikaments zur vorbeugung bzw. behandlung von krankheiten aufgrund erhoehter blutfettwerte
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE69905489D1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
DE69632117D1 (de) Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten
DE69427927D1 (de) Verwendung von Trimetazidin zur Herstellung von Medikamenten für die Behandlung von Gesundheitsstörungen, die durch die Nephrotoxizität von Cyclosporin A bedingt sind.
DE3579642D1 (de) Zusammensetzung zur herstellung eines arzneimittels zur therapeutischen behandlung von hauttrauma.
ATE56360T1 (de) Zusammensetzung zur herstellung eines arzneimittels zur therapeutischen behandlung von hauttrauma.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 600010

Country of ref document: EP